Skip to main content
PMC home page
Journal of the National Medical Association logoLink to Journal of the National Medical Association
. 1998 Jan;90(1):41–45.

Type I collagen as a marker of bone metabolism in sickle cell hemoglobinopathies.

D M Bolarin 1, P Swerdlow 1, A M Wallace 1, L Littsey 1
PMCID: PMC2608298  PMID: 9473928

Abstract

Avascular necrosis of the skeletal system is a complication of sickle cell hemoglobinopathies. Type I collagen, which is synthesized by osteoblasts, comprises about 90% of the total organic matrix of bone. This preliminary study of skeletal changes in sickle cell hemoglobinopathies measured type I collagen formation and degradation using specific radioimmunoassays to determine the plasma concentrations of carboxyterminal propeptide of type I procollagen (PICP) and carboxyterminal pyridinoline cross-linked telopeptide of type I collagen (ICTP), respectively. Plasma ICTP concentrations were increased significantly in sickle cell patients with no clinical or radiologic symptoms of bone complications than in controls. Mean plasma ICTP concentration was moderately high in all patients. Plasma PICP levels did not differ significantly between patients and controls. This preliminary results indicate that measurements of plasma ICTP might be helpful in predicting bone changes in sickle cell hemoglobinopathies and also useful in the early detection of skeletal complications of the disease.

Full text

PDF

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Akesson K. Biochemical markers of bone turnover. A review. Acta Orthop Scand. 1995 Aug;66(4):376–386. doi: 10.3109/17453679508995567. [DOI] [PubMed] [Google Scholar]
  2. Apaja-Sarkkinen M., Autio-Harmainen H., Alavaikko M., Risteli J., Risteli L. Immunohistochemical study of basement membrane proteins and type III procollagen in myelofibrosis. Br J Haematol. 1986 Jul;63(3):571–580. doi: 10.1111/j.1365-2141.1986.tb07535.x. [DOI] [PubMed] [Google Scholar]
  3. Bentley S. A., Alabaster O., Foidart J. M. Collagen heterogeneity in normal human bone marrow. Br J Haematol. 1981 Jun;48(2):287–291. [PubMed] [Google Scholar]
  4. David H. G., Bridgman S. A., Davies S. C., Hine A. L., Emery R. J. The shoulder in sickle-cell disease. J Bone Joint Surg Br. 1993 Jul;75(4):538–545. doi: 10.1302/0301-620X.75B4.8331106. [DOI] [PubMed] [Google Scholar]
  5. Demers L. M., Costa L., Chinchilli V. M., Gaydos L., Curley E., Lipton A. Biochemical markers of bone turnover in patients with metastatic bone disease. Clin Chem. 1995 Oct;41(10):1489–1494. [PubMed] [Google Scholar]
  6. Elomaa I., Virkkunen P., Risteli L., Risteli J. Serum concentration of the cross-linked carboxyterminal telopeptide of type I collagen (ICTP) is a useful prognostic indicator in multiple myeloma. Br J Cancer. 1992 Aug;66(2):337–341. doi: 10.1038/bjc.1992.266. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Eltumi M., Trivedi P., Hobbs J. R., Portmann B., Cheeseman P., Downie C., Risteli J., Risteli L., Mowat A. P. Monitoring of veno-occlusive disease after bone marrow transplantation by serum aminopropeptide of type III procollagen. Lancet. 1993 Aug 28;342(8870):518–521. doi: 10.1016/0140-6736(93)91646-4. [DOI] [PubMed] [Google Scholar]
  8. Eriksen E. F., Charles P., Melsen F., Mosekilde L., Risteli L., Risteli J. Serum markers of type I collagen formation and degradation in metabolic bone disease: correlation with bone histomorphometry. J Bone Miner Res. 1993 Feb;8(2):127–132. doi: 10.1002/jbmr.5650080202. [DOI] [PubMed] [Google Scholar]
  9. Hasselbalch H., Junker P., Hørslev-Petersen K., Lisse I., Bentsen K. D. Procollagen type III aminoterminal peptide in serum in idiopathic myelofibrosis and allied conditions: relation to disease activity and effect of chemotherapy. Am J Hematol. 1990 Jan;33(1):18–26. doi: 10.1002/ajh.2830330105. [DOI] [PubMed] [Google Scholar]
  10. Heikinheimo M., Halila R., Fasth A. Serum procollagen type III is an early and sensitive marker for veno-occlusive disease of the liver in children undergoing bone marrow transplantation. Blood. 1994 May 15;83(10):3036–3040. [PubMed] [Google Scholar]
  11. Hernigou P., Galacteros F., Bachir D., Goutallier D. Deformities of the hip in adults who have sickle-cell disease and had avascular necrosis in childhood. A natural history of fifty-two patients. J Bone Joint Surg Am. 1991 Jan;73(1):81–92. [PubMed] [Google Scholar]
  12. Hernigou P., Galacteros F., Bachir D., Goutallier D. Etude de 164 nécroses épiphysaires (hanches, épaules, genoux) chez 55 patients drépanocytaires. Caractéristiques, aspect épidémiologique et étiopathogénique. Rev Rhum Mal Osteoartic. 1989 Dec;56(12):869–875. [PubMed] [Google Scholar]
  13. Iwegbu C. G., Fleming A. F. Avascular necrosis of the femoral head in sickle-cell disease. A series from the Guinea Savannah of Nigeria. J Bone Joint Surg Br. 1985 Jan;67(1):29–32. doi: 10.1302/0301-620X.67B1.3968138. [DOI] [PubMed] [Google Scholar]
  14. Kylmälä T., Tammela T. L., Risteli L., Risteli J., Kontturi M., Elomaa I. Type I collagen degradation product (ICTP) gives information about the nature of bone metastases and has prognostic value in prostate cancer. Br J Cancer. 1995 May;71(5):1061–1064. doi: 10.1038/bjc.1995.204. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Melkko J., Niemi S., Risteli L., Risteli J. Radioimmunoassay of the carboxyterminal propeptide of human type I procollagen. Clin Chem. 1990 Jul;36(7):1328–1332. [PubMed] [Google Scholar]
  16. Milner P. F., Kraus A. P., Sebes J. I., Sleeper L. A., Dukes K. A., Embury S. H., Bellevue R., Koshy M., Moohr J. W., Smith J. Osteonecrosis of the humeral head in sickle cell disease. Clin Orthop Relat Res. 1993 Apr;(289):136–143. [PubMed] [Google Scholar]
  17. Rao V. M., Mitchell D. G., Rifkin M. D., Steiner R. M., Burk D. L., Jr, Levy D., Ballas S. K. Marrow infarction in sickle cell anemia: correlation with marrow type and distribution by MRI. Magn Reson Imaging. 1989 Jan-Feb;7(1):39–44. doi: 10.1016/0730-725x(89)90322-6. [DOI] [PubMed] [Google Scholar]
  18. Risteli J., Elomaa I., Niemi S., Novamo A., Risteli L. Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen: a new serum marker of bone collagen degradation. Clin Chem. 1993 Apr;39(4):635–640. [PubMed] [Google Scholar]
  19. Sain A., Sham R., Silver L. Bone scan in sickle cell crisis. Clin Nucl Med. 1978 Mar;3(3):85–90. doi: 10.1097/00003072-197803000-00003. [DOI] [PubMed] [Google Scholar]
  20. Sowers M., Eyre D., Hollis B. W., Randolph J. F., Shapiro B., Jannausch M. L., Crutchfield M. Biochemical markers of bone turnover in lactating and nonlactating postpartum women. J Clin Endocrinol Metab. 1995 Jul;80(7):2210–2216. doi: 10.1210/jcem.80.7.7608281. [DOI] [PubMed] [Google Scholar]
  21. Taimela E., Taimela S., Nikkanen V., Irjala K. Accelerated bone degradation in thyroid carcinoma patients during thyroxine treatment, measured by determination of the carboxyterminal telopeptide region of type I collagen in serum. Eur J Clin Chem Clin Biochem. 1994 Nov;32(11):827–831. doi: 10.1515/cclm.1994.32.11.827. [DOI] [PubMed] [Google Scholar]
  22. Taube T., Franssila K., Risteli L., Risteli J., Elomaa I. Monitoring of multiple myeloma and bone marrow fibrosis with aminoterminal propeptide of type III collagen (PIIINP). Br J Haematol. 1992 Sep;82(1):32–37. doi: 10.1111/j.1365-2141.1992.tb04590.x. [DOI] [PubMed] [Google Scholar]
  23. Ware H. E., Brooks A. P., Toye R., Berney S. I. Sickle cell disease and silent avascular necrosis of the hip. J Bone Joint Surg Br. 1991 Nov;73(6):947–949. doi: 10.1302/0301-620X.73B6.1955442. [DOI] [PubMed] [Google Scholar]

Articles from Journal of the National Medical Association are provided here courtesy of National Medical Association

RESOURCES